Discordant Antibody and T-Cell Responses to the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant in Coronavirus Disease 2019 Messenger RNA Vaccine Recipients

Bezawit A. Woldemeskel; Caroline C. Garliss; Tihitina Y. Aytenfisu; Trevor S. Johnston; Andrea L. Cox; Andrew H. Karaba; Joel N. Blankson

doi:10.1093/cid/ciac305

Discordant Antibody and T-Cell Responses to the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant in Coronavirus Disease 2019 Messenger RNA Vaccine Recipients

Bezawit A. Woldemeskel, Caroline C. Garliss, Tihitina Y. Aytenfisu, Trevor S. Johnston, Andrea L. Cox, Andrew H. Karaba, Joel N. Blankson

School of Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

We compared antibody and T-cell responses against the severe acute respiratory syndrome coronavirus 2 vaccine strain spike protein to responses against the Omicron variant in 15 messenger RNA vaccine recipients. While these individuals had significantly lower levels of antibodies that inhibited Omicron spike protein binding to ACE2, there was no difference in T-cell responses.

Original language	English (US)
Pages (from-to)	1652-1654
Number of pages	3
Journal	Clinical Infectious Diseases
Volume	75
Issue number	9
DOIs	https://doi.org/10.1093/cid/ciac305
State	Published - Nov 1 2022

Keywords

COVID-19
Omicron
SARS-CoV-2
T cells
antibodies

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

Access to Document

10.1093/cid/ciac305

Cite this

Woldemeskel, B. A., Garliss, C. C., Aytenfisu, T. Y., Johnston, T. S., Cox, A. L., Karaba, A. H., & Blankson, J. N. (2022). Discordant Antibody and T-Cell Responses to the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant in Coronavirus Disease 2019 Messenger RNA Vaccine Recipients. Clinical Infectious Diseases, 75(9), 1652-1654. https://doi.org/10.1093/cid/ciac305

Discordant Antibody and T-Cell Responses to the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant in Coronavirus Disease 2019 Messenger RNA Vaccine Recipients. / Woldemeskel, Bezawit A.; Garliss, Caroline C.; Aytenfisu, Tihitina Y. et al.
In: Clinical Infectious Diseases, Vol. 75, No. 9, 01.11.2022, p. 1652-1654.

Research output: Contribution to journal › Article › peer-review

Woldemeskel, BA, Garliss, CC, Aytenfisu, TY, Johnston, TS, Cox, AL , Karaba, AH & Blankson, JN 2022, 'Discordant Antibody and T-Cell Responses to the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant in Coronavirus Disease 2019 Messenger RNA Vaccine Recipients', Clinical Infectious Diseases, vol. 75, no. 9, pp. 1652-1654. https://doi.org/10.1093/cid/ciac305

@article{ef52b72dcba54986adce6c5bc503fb3f,

title = "Discordant Antibody and T-Cell Responses to the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant in Coronavirus Disease 2019 Messenger RNA Vaccine Recipients",

abstract = "We compared antibody and T-cell responses against the severe acute respiratory syndrome coronavirus 2 vaccine strain spike protein to responses against the Omicron variant in 15 messenger RNA vaccine recipients. While these individuals had significantly lower levels of antibodies that inhibited Omicron spike protein binding to ACE2, there was no difference in T-cell responses.",

keywords = "COVID-19, Omicron, SARS-CoV-2, T cells, antibodies",

author = "Woldemeskel, {Bezawit A.} and Garliss, {Caroline C.} and Aytenfisu, {Tihitina Y.} and Johnston, {Trevor S.} and Cox, {Andrea L.} and Karaba, {Andrew H.} and Blankson, {Joel N.}",

year = "2022",

month = nov,

day = "1",

doi = "10.1093/cid/ciac305",

language = "English (US)",

volume = "75",

pages = "1652--1654",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "9",

}

TY - JOUR

T1 - Discordant Antibody and T-Cell Responses to the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant in Coronavirus Disease 2019 Messenger RNA Vaccine Recipients

AU - Woldemeskel, Bezawit A.

AU - Garliss, Caroline C.

AU - Aytenfisu, Tihitina Y.

AU - Johnston, Trevor S.

AU - Cox, Andrea L.

AU - Karaba, Andrew H.

AU - Blankson, Joel N.

PY - 2022/11/1

Y1 - 2022/11/1

N2 - We compared antibody and T-cell responses against the severe acute respiratory syndrome coronavirus 2 vaccine strain spike protein to responses against the Omicron variant in 15 messenger RNA vaccine recipients. While these individuals had significantly lower levels of antibodies that inhibited Omicron spike protein binding to ACE2, there was no difference in T-cell responses.

AB - We compared antibody and T-cell responses against the severe acute respiratory syndrome coronavirus 2 vaccine strain spike protein to responses against the Omicron variant in 15 messenger RNA vaccine recipients. While these individuals had significantly lower levels of antibodies that inhibited Omicron spike protein binding to ACE2, there was no difference in T-cell responses.

KW - COVID-19

KW - Omicron

KW - SARS-CoV-2

KW - T cells

KW - antibodies

UR - http://www.scopus.com/inward/record.url?scp=85141004942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85141004942&partnerID=8YFLogxK

U2 - 10.1093/cid/ciac305

DO - 10.1093/cid/ciac305

M3 - Article

C2 - 35438751

AN - SCOPUS:85141004942

SN - 1058-4838

VL - 75

SP - 1652

EP - 1654

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 9

ER -

Discordant Antibody and T-Cell Responses to the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant in Coronavirus Disease 2019 Messenger RNA Vaccine Recipients

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this